It would have been nice if they just listed 50 at the start instead of dropping to 30 and then raising to 50, at least the remaining 10 comes with more flexibility. Also 300 for safety, counting all that have been on 24 weeks. I wonder how many have been on 24 weeks from past studies? Looks like they get an interim PE report based on the 40 which helps greatly against selling pressure, if they had to wait on the entire 50 we might have tested lows.
The FDA accepted the 40 patients currently enrolled in CytoDyn’s Phase 2b/3 pivotal combination trial as evaluable and further agreed that the trial’s Data Monitoring Committee can conduct an interim efficacy analysis of primary endpoint
Market Data 
Markets 
AI
